Doripenem indications and usage: Difference between revisions
(Created page with "__NOTOC__ {{Doripenem}} {{CMG}} ==Indications And Usage== To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacte...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Doripenem}} | {{Doripenem}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{SS}} | ||
==Indications and Usage== | |||
To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting and modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. | To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting and modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. | ||
| Line 12: | Line 13: | ||
===Complicated Urinary Tract Infections, Including Pyelonephritis=== | ===Complicated Urinary Tract Infections, Including Pyelonephritis=== | ||
DORIBAX® (doripenem for injection) is indicated as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae,Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii.<ref>{{Cite web | last = | first = |title =http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022106s014lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022106s014lbl.pdf | publisher =|date = | accessdate = }}</ref> | DORIBAX® (doripenem for injection) is indicated as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by [[Escherichia coli]] including cases with concurrent bacteremia, [[Klebsiella pneumoniae]], [[Proteus mirabilis]], [[Pseudomonas aeruginosa]], and [[Acinetobacter baumannii]].<ref>{{Cite web | last = | first = |title =http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022106s014lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022106s014lbl.pdf | publisher =|date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
Latest revision as of 22:10, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Indications and Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting and modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Complicated Intra-Abdominal Infections
DORIBAX® (doripenem for injection) is indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis,Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros.
Complicated Urinary Tract Infections, Including Pyelonephritis
DORIBAX® (doripenem for injection) is indicated as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022106s014lbl.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.